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S U M M A R Y
Background: In the face of increasing treatment options for extended-spectrum beta-lactamase-
producing Klebsiella pneumoniae (ESBL-Kp) hemodialysis (HD) access-related bacteremia, the difference
in clinical effectiveness between ertapenem and ﬂomoxef remains unclear. We conducted this
retrospective study to determine their efﬁcacies and treatment outcomes.
Methods: Patients on maintenance HD with ﬁstula-, graft-, or catheter-related ESBL-Kp bacteremia were
enrolled. Data related to clinical features and antibiotic treatments were collected. Outcome was
determined by mortality resulting from bacteremia during the 14-day period after the collection of the
ﬁrst positive blood culture for ﬂomoxef-susceptible ESBL-Kp.
Results: The 64 patients studied had severe septicemia as determined by the Pitt bacteremia score; 50%
(32/64) were in the intensive care unit (ICU) at the time of bacteremia. Old age (>65 years; 57.8%),
malnutrition (albumin < 3.5 g/dl; 92.2%), a history of severe illnesses (deﬁned by shock, intubation, or
ICU stay; 82.5%), and prolonged hospitalization prior to the onset of bacteremia (>30 days; 75%) were
also highly prevalent. The study population comprised nine ﬁstula-, 10 graft-, and 45 HD catheter-
related bacteremia cases, and the mortality rate was high (38/64, 59.4%). The mortality rate was
signiﬁcantly higher in the ﬂomoxef treatment group than in the ertapenem treatment group (22/30, 73%
vs. 16/34, 47%, p < 0.05). Among patients with catheter-related bacteremia, multivariate analyses
revealed that ﬂomoxef use (odds ratio (OR) 2.52, 95% conﬁdence interval (CI) 1.34–35.17) and Pitt
bacteremia score (OR 4.37, 95% CI 1.28–5.26) were independently associated with mortality.
Conclusions: In accordance with our previous study, our results have demonstrated the inferiority of
ﬂomoxef to carbapenems in the treatment of HD access-related ESBL-Kp bacteremia and provide an
insight into the possibility of using ertapenem rather than ﬂomoxef as an initial or de-escalating therapy
for infections caused by ESBL-producing bacteria.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Numerous reports implicate the vascular access in up to 48–73% of
all bacteremia in HD patients.1,2 A previous study recognized HD
access-related extended-spectrum beta-lactamase (ESBL)-producing
Klebsiella pneumoniae (ESBL-Kp) bacteremia to cause high mortality inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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patients initially received ineffective empiric antibiotics and there was
a discrepancy in outcomes between patients receiving different
effective antibiotics. Group 2 carbapenems (imipenem or meropenem)
showed superior efﬁcacy than ﬂomoxef in treating these vulnerable
patients.
The currently recommended therapy for infection caused by ESBL-
producing organisms consists of group 2 carbapenems (e.g., imipenem
and meropenem).4,5More recent studies have shown that ertapenem,
a group 1 carbapenem, may be used successfully for ESBL-associated
infection with favorable clinical response and microbiological cure
rates6 and provides comparable efﬁcacy to group 2 carbapenems.7
Cephamycins (i.e., cefmetazole, cefotetan, and ﬂomoxef), character-
ized by their 7-a-methoxy b-lactam, have been reported to be highly
active in vitro against both low inocula (105–106 CFU/ml) and high
inocula (107–108 CFU/ml) of TEM- or SHV-producing Enterobacter-
iaceae.8 In a retrospective study, treatment with either ﬂomoxef or a
group 2 carbapenem in patients with ﬂomoxef-susceptible ESBL-Kp
bacteremia was reported  to be similarly effective.9 Unfortunately,
controversy remains regarding the optimal treatment, and few clinical
reports comparing the treatment efﬁcacy of cephamycins and
carbapenems have been published.10
Because the differences in clinical effectiveness between
ertapenem and ﬂomoxef for HD access-related ESBL-Kp bacter-
emia in patients on MHD have not yet been studied, we conducted
this 9-year retrospective study to compare the outcomes of
patients treated with either ﬂomoxef or ertapenem.
2. Subjects and methods
2.1. Study population and design
Adult MHD patients admitted during the 9-year period from
January 2001 to December 2009 who developed a nosocomial HD
access-related infection secondary to ESBL-Kp were included. The
eligibility criteria was the presence of HD access (including
arteriovenous ﬁstula, graft or catheter) -related ﬂomoxef-suscepti-
ble ESBL-Kp bacteremia. The following details were obtained from
the medical charts: patient clinical characteristics, biochemical data,
sites of ESBL-Kp infection (blood, HD catheter tip, pus from HD
catheter exit site, and pus from ﬁstula or graft wounds), and
outcomes. Only patients treated with either ﬂomoxef or ertapenem
were included. For each patient included, ﬂomoxef or ertapenem
was administered for at least 2 days, starting within 5 days after
receiving the ﬁnalized blood culture results. Individual patients
without blood cultures that grew ESBL-Kp and severely ill patients
who died rapidly without having received ertapenem or ﬂomoxef for
at least 2 days were excluded. Variables used for the assessment of
severity of illness included the Pitt bacteremia score and comorbid
conditions (e.g., poor nutrition, length of prior hospital stay (LOS),
and intensive care unit (ICU) stay at the time of bacteremia).
Mortality resulting from bacteremia within 14 days after the day the
ﬁrst positive blood culture that grew ﬂomoxef-susceptible ESBL-Kp
was collected, was used to determine the outcome. The study was
approved by the institutional review board of Kaohsiung Chang
Gung Memorial Hospital (study ID: CGMH-IRB-101-1595B).
2.2. Microbiology
All K. pneumoniae isolates were identiﬁed by standard methods,
and the presence of ESBLs was evaluated using the Clinical and
Laboratory Standards Institute (CLSI) criteria for ESBL screening
and the disk conﬁrmation test.11 Minimum inhibitory concentra-
tions (MICs) 2 mg/l for ertapenem and 8 mg/l for ﬂomoxef were
considered to indicate susceptibility.12,132.3. Deﬁnitions
Nosocomial bacteremia was deﬁned as bacteremia
occurring > 48 h after admission to the hospital. HD access
infections were deﬁned in the presence of local signs (pus or
redness) at the vascular access site, with or without a positive
culture from the catheter tip or pus, or a positive blood culture with
no known source other than the vascular access. ESBL-Kp bacteremia
was deﬁned by the isolation of ESBL-Kp from blood cultures. Empiric
antibiotic was deﬁned as the antibiotic therapy started at the time
blood cultures were drawn. Deﬁnitive antibiotic was deﬁned as the
antibiotic therapy administered subsequent to the receipt of ﬁnal
blood culture results. Effective antimicrobial therapy for ﬂomoxef-
susceptible ESBL-Kp bacteremia in this study was deﬁned as
treatment with ertapenem or ﬂomoxef—after determining the
antibiotic susceptibility of the blood isolates. Signiﬁcant underlying
diseases were deﬁned as a medical history of diabetes mellitus, liver
cirrhosis, malignancy, or congestive heart failure.
2.4. Statistical analyses
All statistical analyses were performed using SPSS software
program for Windows version 11.5 (SPSS Inc., Chicago, IL, USA).
Continuous variables were each expressed as the mean  standard
deviation (SD) and were analyzed using the Student’s t-test. The
statistical difference in the frequency of occurrence of the variants in
patients with HD catheter-related bacteremia (CRB) between
subgroups was assessed with the Chi-square test or Fisher’s exact
test. A logistic regression model was used to estimate the effects of
multiple factors associated with mortality in the univariate analyses.
Variables with p  0.1 in the univariate analysis between patients
who died and those who survived were entered for further
assessment. Estimated odds ratios (ORs) and 95% conﬁdence intervals
(CIs) were obtained from this model. For all analyses, two-sided tests
of signiﬁcance were used, with p < 0.05 considered signiﬁcant.
3. Results
A total of 64 MHD patients with HD access-related bacteremia
who met the inclusion criteria were identiﬁed during the study
period. The demographic and clinical data of these patients are
summarized in Table 1. In addition to 45 patients with HD CRB,
there were nine patients with ﬁstula-related bacteremia and
10 patients with graft-related bacteremia. Most of these patients
were male (47/64, 73.4%), and old age (>65 years; 57.8%),
malnutrition (albumin < 3.5 g/dl; 92.2%), a history of severe illness
(deﬁned by shock, intubation, or ICU stay; 82.5%), and prolonged
hospitalization prior to the onset of bacteremia (>30 days; 75%)
were highly prevalent. Many patients also had signiﬁcant
underlying diseases (diabetes mellitus 46.9%, liver cirrhosis
14.1%, congestive heart failure 31.3%, and malignancy 10.9%)
and prior use of broad-spectrum antibiotics (third-generation
cephalosporin 64.1%). Most patients were initially hospitalized due
to the onset of an infectious disease (39/64, 60.9%). At the onset of
bacteremia, these patients had a critical illness (deﬁned as a Pitt
bacteremia score 4 points), with a mean  SD Pitt bacteremia
score of 5.3  1.78. Thirty-two (32/64, 50%) patients were accommo-
dated in an ICU at the time of bacteremia. The overall mortality rate
was high (38/64, 59.4%), and patients with graft infection had the
highest Pitt bacteremia score and the highest rate of mortality (7/10,
70%). With regard to the use of empiric antibiotics, the majority (38/
64, 59.4%) did not receive effective antibiotic therapy, consisting of
either ﬂomoxef or ertapenem within 5 days after blood cultures were
obtained, at the onset of bacteremia. A total of 53.1% (34/64) of
patients were treated with ertapenem and 46.9% (30/64) with
ﬂomoxef as the deﬁnitive effective antibiotic.
Table 1
Comparisons of demographic and clinical data between the groups of different hemodialysis access-related ESBL-Kp bacteremia
Source of infection
HD catheter Fistula Graft All
Number of cases 45 9 10 64
Male, n (%) 34 (75.6) 6 (66.7) 7 (70) 47 (73.4)
Age, years, mean  SD 65.2  11.2 62  9.3 67.1  8.6 65.0  10.1
Patients aged > 65 years, n (%) 26 (57.8) 4 (44.4) 7 (70) 37 (57.8)
Admission for infectious diseases, n (%) 25 (55.6) 6 (66.7) 8 (80) 39 (60.9)
Signiﬁcant underlying diseases, n (%)
Diabetes mellitus 17 (37.8) 5 (55.6) 8 (80) 30 (46.9)
Liver cirrhosis 5 (11.1) 2 (22.2) 2 (20) 9 (14.1)
Congestive heart failure 11 (24.4) 4 (44.4) 5 (50) 20 (31.3)
Malignancy 4 (8.9) 2 (22.2) 1 (10) 7 (10.9)
Comorbid conditions, n (%)
Poor nutritiona 42 (93.3) 8 (88.9) 9 (90) 59 (92.2)
Prior antibiotic useb 38 (84.4) 7 (77.8) 7 (70) 52 (81.3)
Previous severe illnessc 35 (77.8) 6 (66.7) 6 (75) 47 (82.5)
Prolonged hospitalization (>30 days), n (%) 35 (77.8) 6 (66.7) 7 (70) 48 (75)
Prior use of third-generation cephalosporin, n (%) 28 (62.2) 6 (66.7) 7 (70) 41 (64.1)
ICU stay at the time of bacteremia, n (%) 21 (46.7) 5 (55.6) 6 (60) 32 (50)
Pitt bacteremia score, mean  SD 5.1  1.41 5.3  1.52 6.2  2.6 5.3  1.78
Antibiotics after onset of bacteremia, n (%)
Effective antibiotics within 5 days 18 (40) 4 (44.4) 4 (40) 26 (40.6)
Use of ﬂomoxef/ertapenem as effective antibiotic 19 (42.2)/26 (57.8) 5 (55.6)/4 (44.4) 6 (60)/4 (40) 30 (46.9)/34 (53.1)
Mortality, n (%) 27 (60) 4 (44.4) 7 (70) 38 (59.4)
ESBL-Kp, extended-spectrum beta-lactamase-producing Klebsiella pneumoniae; HD, hemodialysis; SD, standard deviation; ICU, intensive care unit.
a Albumin < 3.5 g/dl.
b Including extended-spectrum cephalosporins, aztreonam, ﬂuoroquinolones, trimethoprim/sulfamethoxazole, or aminoglycosides.
c Includes shock, intubation, and ICU stay.
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ment of severity of illness, and outcomes were compared between
the two treatment groups (Table 2). When compared with the
ertapenem group, patients treated with ﬂomoxef had more ﬁstula-
and graft-related infections and carried a higher risk of mortality
(p < 0.05). For patients with ﬁstula or graft infections, surgical
interventions (wound debridement and/or removal of the infected
ﬁstula or graft) were performed in eight (8/11, 73%) patients
treated with ﬂomoxef and in three (3/8, 38%) treated with
ertapenem. Since the extent and perioperative risk of surgery
might affect the survival of patients with ﬁstula or graft infections,
we only analyzed patients with CRB.
The demographic and clinical data of patients with CRB are
summarized in Table 3. Most of the patients were elderly and the
overall mortality rate was high (27/45, 60%). Patients who died had
signiﬁcantly lower levels of serum albumin, a longer LOS, and
longer duration of catheter-dependent HD (all p < 0.05). ATable 2
Comparisons of patient clinical characteristics, variables used for the assessment of
illness severity, and outcomes between the ertapenem and ﬂomoxef treatment
groups
Ertapenem Flomoxef
Number of cases 34 30
Source of infection, n
HD catheter 26 19
Fistula 4 5
Graft 4 6
Comorbid conditions, n (%)
Poor nutritiona 31 (91) 28 (93)
Previous severe illnessb 24 (71) 23 (77)
Prolonged hospitalization (>30 days) 25 (74) 23 (77)
ICU stay at the time of bacteremia 17 (50) 15 (50)
Pitt bacteremia score, mean  SD 5.3  1.37 5.4  1.65
Effective antibiotics within 5 days, n (%) 14 (41) 12 (40)
Mortality, n (%)c 16 (47) 22 (73)
HD, hemodialysis; ICU, intensive care unit; SD, standard deviation.
a Albumin < 3.5 g/dl.
b Includes shock, intubation, and ICU stay.
c p < 0.05.signiﬁcantly higher Pitt bacteremia score (4.12 vs. 5.75) and
prevalence of ICU stay (27.8% vs. 59.3%), both reﬂecting the
severity of the septicemia, were also noted in the group of patients
who died (both p < 0.05). The prescription of appropriate empiric
and deﬁnitive antibiotic therapy indeed signiﬁcantly affected the
outcome. Mortality was signiﬁcantly associated with ﬂomoxef
treatment and not having received effective antibiotic therapy
within 5 days after the onset of bacteremia.
The results of the multivariate analysis examining risk factors
for mortality associated with CRB are given in Table 4. Variables
that were determined to be signiﬁcantly associated with mortality
at 14 days after the date the ﬁrst positive blood culture was
collected on univariate analysis were subjected to multivariate
analysis. Flomoxef treatment (OR 2.52, 95% CI 1.34–35.17) and Pitt
bacteremia score (OR 4.37, 95% CI 1.28–5.26) were independently
associated with increased mortality.
4. Discussion
No strict guidelines or consensus indicates the preferred
therapeutic treatment for ESBL-producing Enterobacteriaceae-
related infections, especially in immunocompromised individuals
like HD patients. For infections secondary to ESBL-producing
organisms, a higher clinical failure rate14 and mortality rate15 have
been associated with cephalosporin treatment, and the overuse of
cephalosporins has been shown to lead to increased bacterial
resistance to many classes of beta-lactam and non-beta-lactam
antibiotics. Although a few small retrospective trials have
demonstrated that group 2 carbapenems show relative superiority
over other agents for the treatment of infections caused by ESBL-
producing organisms,7 the extensive use of these antibiotics may
result in the outbreak of infections related to carbapenem-
resistant strains such as Acinetobacter baumanii,16 Pseudomonas
aeruginosa,17 and Stenotrophomonas maltophilia.18 The emergence
of multi-drug resistance in these virulent pathogens poses
challenging infection-control issues and has signiﬁcantly ham-
pered efforts to devise effective empiric or directed antibiotic
treatment regimens.
Table 3
Comparisons of demographic and clinical data between patients who died and those who survived of the 45 patients with catheter-related bacteremia
Variable Survived
(n = 18)
Died
(n = 27)
p-Value Total
(n = 45)
Age, years, mean  SD 64.2  7.2 65.9  12.1 NS 65.2  11.2
Male, n (%) 13/18 (72.2) 21/27 (77.8) NS 34/45 (75.6)
Patients aged > 65 years, n (%) 9/18 (50) 17/27 (63) NS 26/45 (57.8)
Flomoxef treatment, n (%) 3 (16.7) 16 (59.3) 0.015 19 (42.2)
Treatment within 5 days, n (%) 11 (61.1) 7 (25.9) 0.029 18 (40)
Pitt bacteremia score, mean  SD 4.12  1.14 5.75  1.67 0.007 5.1  1.41
Serum albumin, g/dl, mean  SD 2.83  0.54 2.32  0.75 0.037 2.52  0.71
Hemoglobin, g/dl, mean  SD 9.21  0.65 9.33  1.81 NS 9.28  1.51
Hospital days before onset, mean  SD 52  31.2 112.9  64.5 0.045 88.5  59.1
Duration of catheter-dependent HD, days, mean  SD 26.2  8.9 41.6  13.1 0.031 35.4  11.2
ICU stay at the time of bacteremia, n (%) 5 (27.8) 16 (59.3) 0.022 21 (46.7)
SD, standard deviation; NS, not signiﬁcant; HD, hemodialysis; ICU, intensive care unit.
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omethylthioacetamido group at position 7, which improves its in
vitro activity against ESBL-producing Enterobacteriaceae.8,19 Erta-
penem is a new carbapenem with superior pharmacokinetics and
shares similar structural features with meropenem, allowing it to
have broad-spectrum activity with resistance to nearly all b-
lactamases.20 However, both ertapenem and ﬂomoxef have limited
activity against P. aeruginosa and A. baumannii, which makes them
not optimal for infections caused by nosocomial pathogens. In HD
patients, both intravenous ertapenem and ﬂomoxef can be given
once-daily at dosages of 500 mg and 1 g, respectively, which may
be an advantage of prescription. However, their efﬁcacies for the
treatment of HD access-related ESBL-Kp bacteremia in MHD
patients are still unclear.
Although our study was limited by its retrospective design and
small sample size, it indeed demonstrated that the prescription of
an appropriate antibiotic is critical in the light of our ﬁnding that
treatment with ﬂomoxef was an independent risk factor for
increased mortality (on multivariate analysis) in these vulnerable
patients. As in our previous study,3 the research data in this study
were derived from our population of HD patients with HD access-
related ESBL-Kp bacteremia and most of them were treated with
ﬂomoxef, imipenem, meropenem, or ertapenem. After an extensive
literature review, we found there to be very limited data regarding
this issue, therefore we conducted these two studies using a
similar methodology and statistical analysis methods.
Our study results have demonstrated an inferiority of ﬂomoxef to
carbapenems in the treatment of HD access-related ESBL-Kp
bacteremia. Although ﬂomoxef is stable to hydrolysis by ESBL-
producing Enterobacteriaceae, there is a general reluctance to use this
agent because some isolates may decrease the expression of outer
membrane proteins, thus creating resistance to this agent during
therapy.10 It is not surprising that the loss of effectiveness of ﬂomoxef,
if present, while treating ESBL-Kp bacteremia in critically ill HD
patients leads to increased treatment failure and mortality. As a result
of this major concern, the carbapenems have become widely
recognized as the drug class of ﬁrst choice for the treatment of
serious infections caused by ESBL-producing Enterobacteriaceae. Our
study indicates the possibility of using ertapenem rather than ﬂomoxef
as an initial or de-escalating therapy for infections caused by ESBL-
producing bacteria. Because of the risk of selecting for resistance, initialTable 4
Results of the multivariate analysis examining risk factors for mortality associated
with catheter-related bacteremia
Mortality risk factor p-Value OR (95% CI)
Flomoxef treatment (vs. ertapenem) 0.021 2.52 (1.34–35.17)
Pitt bacteremia score (per 1-point increment) 0.009 4.37 (1.28–5.26)
OR, odds ratio; CI, conﬁdence interval.empirical broad-spectrum treatment with imipenem or meropenem
should be de-escalated to a narrow-spectrum agent once the identity
and susceptibility proﬁles of the infecting pathogens are known.
Limiting the use of imipenem and meropenem may consequently
prevent the emergence of carbapenem resistance in A. baumannii and
P. aeruginosa.
In addition to the risk of immunocompromise, HD patients may
be rendered susceptible to ESBL-related infection by frequent
vascular catheterization, catheter manipulation, and the need for
broad-spectrum antibiotics during prolonged hospitalization.
Although HD has been recognized as a risk factor for the
acquisition of ESBL infections,4,21 there is limited information
regarding the clinical characteristics associated with HD access-
related ESBL-Kp bacteremia in MHD patients. Most of the patients
with bacteremia in the present study were elderly, malnourished,
and had a history of severe illness and prolonged hospitalization.
These patients were also critically ill, as determined by the Pitt
bacteremia score, and had high prevalence rates of signiﬁcant
underlying diseases and were in the ICU at the time of bacteremia;
therefore, they had a high mortality rate (38/64, 59.4%). Only 40.6%
of these critically ill patients received effective antibiotics within
5 days after the date the ﬁrst positive blood culture for ESBL-Kp
was collected, which may have contributed to the high mortality
rate.
Prolonged hospitalization has been recognized as a risk factor
for ESBL infection,15 and hypoalbuminemia has also been found to
increase the likelihood of CRB in HD patients.22 In the present
study, both longer LOS and a lower serum albumin level were
associated with high mortality in patients with CRB. A longer
duration of catheter-dependent HD was additionally determined
to be a risk factor for increased mortality. These ﬁndings suggest
that shortening the duration of catheter-dependent HD may
decrease the probability of CRB secondary to ESBL-producing
bacteria and improve the prognosis. The signiﬁcantly higher Pitt
bacteremia score and prevalence rate of ICU stay at the time of
bacteremia in the group of patients who died was not surprising.
Because MHD patients with HD access-related ESBL-Kp bacteremia
were mostly immunocompromised and critically ill, their mortali-
ty rate was determined by these parameters, which reﬂected the
severity of the septicemia.
The use of effective antibiotics such as carbapenems during the
5-day period after the onset of bacteremia due to an ESBL-
producing organism has been reported to be associated with lower
mortality.23 Unfortunately, most of our patients initially received
ineffective empiric antibiotics and the limitation of the retrospec-
tive design of this study made a comparison of quantitative
outcomes between treatment groups infeasible. However, the
lower percentage of patients receiving effective empiric antibiotics
reﬂects our collective unawareness of the signiﬁcance of these
emerging strains and the very limited information regarding this
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with effective antibiotics within 5 days after the onset of
bacteremia and the use of ertapenem improved the prognosis in
patients with CRB.
In conclusion, this is the ﬁrst study to suggest ertapenem rather
than ﬂomoxef as the ﬁrst choice for the empiric or directed therapy
of critically ill MHD patients with HD access-related ESBL-Kp
bacteremia. We stress that HD patients with a critical illness are
susceptible to ESBL-Kp HD access-related bacteremia and have
poor outcomes.
Conﬂict of interest: The authors declare that they have no
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